Lipid Nanoparticles With Lysophosphatidylcholine For T Cell Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing lipid nanoparticle (LNP) formulations for vaccine delivery induce limited antigen-specific T cell responses, as they do not effectively hyperactivate dendritic cells to secrete IL-1β and enhance long-lived T cell responses.
Innovation Solution
The use of lipid nanoparticles comprising a lysophosphatidylcholine (LPC) compound with a single acyl chain and at least one further lipid, in combination with a TLR7/8 agonist, to hyperactivate mammalian dendritic cells, thereby enhancing IL-1β secretion and T cell responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional LNP formulations are used for vaccine delivery, then antigen-specific antibody responses are induced, but antigen-specific T cell responses are limited
Solution Approach 1:
The patent modifies the lipid composition parameters of the LNP formulation by incorporating specific lipids (e.g., phosphatidylcholine, phosphatidylethanolamine, cholesterol) in defined ratios to change the biological activity and cellular interaction properties, thereby enhancing T cell response while maintaining antibody response
Solution Approach 2:
The patent uses composite lipid nanoparticle formulations combining multiple lipid components working synergistically to achieve both B cell antibody activation and T cell activation, resolving the contradiction between the two response types
2Reliability
If dendritic cells are activated to enhance T cell responses, then long-lived T cell responses are improved, but IL-1β secretion is limited
Solution Approach 1:
The patent adjusts the activation parameters of dendritic cells through specific lipid compositions and adjuvant combinations that optimize both IL-1β secretion and T cell response generation, achieving high levels of both without compromise
Data Source
AI summary
The present disclosure relates to lipid nanoparticles comprising a lysophosphatidylcholine (LPC) compound and at least one further lipid, and uses thereof in hyperactivating mammalian dendritic cells, such as human dendritic cells. The present disclosure also relates to compositions comprising lipid nanoparticles comprising a LPC and at least on further lipid, in which the compositions comprise one or more of a pathogen recognition receptor agonist, an antigen, and mammalian dendritic cells, as well as methods for production and use of the compositions.